Weight Loss and Improvements in Markers of Metabolic Risk in Overweight and Obese Subjects Completing 56 Weeks of Treatment with Naltrexone SR/Bupropion SR

被引：0
|
作者：
Fujioka, Ken
Billes, Sonja K.
Burns, Colleen
Harris-Collazo, Raul
Kim, Dennis D.
Dunayevich, Eduardo
Greenway, Frank L.
机构：
来源：
DIABETES | 2011年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1928-P
引用
收藏
页码：A520 / A521
页数：2
相关论文
共 50 条
  • [31] Weight loss and improvements in cardiometabolic outcomes with extended-release phentermine/topiramate treatment in overweight/obese subjects with type 2 diabetes
    Astrup, A. V.
    Oppert, J. -M.
    Peterson, C. A.
    DIABETOLOGIA, 2012, 55 : S284 - S285
  • [32] REDUCTION OF CARDIOVASCULAR RISK FACTORS BY MAGNITUDE OF WEIGHT LOSS IN OBESE AND OVERWEIGHT SUBJECTS WITH ≥2 COMORBIDITIES
    Cheskin, Lawrence J.
    Bowden, Charles H.
    JOURNAL OF GENERAL INTERNAL MEDICINE, 2013, 28 : S168 - S168
  • [33] Once-daily, controlled-release phentermine/topiramate (PHEN/TPM CR) results in significant weight loss and risk factor improvement in overweight/obese subjects over 56 weeks
    Aronne, L. J.
    Troupin, B.
    Day, W. W.
    DIABETES OBESITY & METABOLISM, 2010, 12 : 51 - 52
  • [34] An open-label trial on the efficacy and tolerability of naltrexone/bupropion SR for treating altered eating behaviours and weight loss in binge eating disorder
    Elvira Anna Carbone
    Mariarita Caroleo
    Marianna Rania
    Giuseppina Calabrò
    Filippo Antonio Staltari
    Renato de Filippis
    Matteo Aloi
    Francesca Condoleo
    Franco Arturi
    Cristina Segura-Garcia
    Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity, 2021, 26 : 779 - 788
  • [35] An open-label trial on the efficacy and tolerability of naltrexone/bupropion SR for treating altered eating behaviours and weight loss in binge eating disorder
    Carbone, Elvira Anna
    Caroleo, Mariarita
    Rania, Marianna
    Calabro, Giuseppina
    Staltari, Filippo Antonio
    de Filippis, Renato
    Aloi, Matteo
    Condoleo, Francesca
    Arturi, Franco
    Segura-Garcia, Cristina
    EATING AND WEIGHT DISORDERS-STUDIES ON ANOREXIA BULIMIA AND OBESITY, 2021, 26 (03) : 779 - 788
  • [36] Naltrexone SR/Bupropion SR Combination (NB) Therapy Shifts Subjects From the Obese to the Non-Obese Body Mass Index (BMI) Classes: From the COR-II Phase 3, Double-Blind, Placebo-Controlled, 56-Week Study
    Rubino, Domenica
    Apovian, Caroline M.
    Still, Christopher D.
    Mignon, Laurence
    Burns, Colleen
    Harris-Collazo, Raul
    Dunayevich, Eduardo
    Kim, Dennis D.
    OBESITY, 2010, 18 : S156 - S156
  • [37] Modest improvements in weight maintenance on a low-glycaemic index (G1) diet following weight loss in overweight and obese subjects
    Philippou, E.
    Neary, N. M.
    Chaudhri, O. B.
    Brynes, A. E.
    Dornhorst, A.
    Leeds, A. R.
    Hickson, M.
    Frost, G. S.
    PROCEEDINGS OF THE NUTRITION SOCIETY, 2007, 66 : 75A - 75A
  • [38] Metabolic syndrome risk factor responses during a residential weight loss camp for overweight and obese children
    Hobkirk, J. P.
    King, R. F. G. J.
    Radley, D.
    Mackreth, P. K.
    Cooke, C. B.
    Barth, J. H.
    Gately, P. J.
    ATHEROSCLEROSIS, 2006, 188 (01) : S5 - S5
  • [39] Weight loss on sibutramine treatment reduces risk of coronary heart disease in obese subjects
    Lauterbach, KW
    Evers, T
    CIRCULATION, 2000, 102 (18) : 849 - 849
  • [40] Effect on Body Weight of Naltrexone/Bupropion in Overweight and Obese Participants with Type 2 Diabetes and Cardiovascular Risk Factors in a Large, Randomized, Double-Blind Study
    Smith, Steven R.
    Buse, John B.
    Gilder, Kye
    Shan, Kevin
    Halseth, Amy
    DIABETES, 2017, 66 : A556 - A556
12345